Quaaludes

Description

Methaqualone was first synthesised in India in 1951 during a search for new antimalarial drugs. It turned out to have no useful antimalarial activity but was found to be a strong sedative-hypnotic, and by the early 1960s it was being marketed under the brand name Mandrax (methaqualone combined with the antihistamine diphenhydramine) as a supposedly "safer", non-addictive alternative to barbiturates for insomnia and anxiety. This turned out to be wrong and methaqualone has a similar dependence and overdose profile to barbiturates, and by the late 1960s and through the 1970s it had become one of the most widely misused prescription sedatives in both the UK and US. Most commonly sold in the US under the brand name Quaalude and used recreationally at clubs (hence "disco biscuits"). Rising rates of addiction, overdose, and fatal poisoning, especially in combination with alcohol, led to it being progressively tightened and eventually banned from legal manufacture in most countries by the mid-1980s.

Genuine pharmaceutical-grade methaqualone has been hard to obtain in the UK/US illicit market for decades. Outside South Africa (see History), tablets or powder sold as "quaaludes" or "Mandrax" today are frequently something else entirely commonly benzodiazepines, other sedatives, or diphenhydramine-based mixes sold under a recognisable brand name rather than being the genuine drug. This should be treated as more likely than not currently rather than a possibility if buying outside South Africa. Recent Wedinos data showed samples containing Methoxyqualone rather than methaqualone available in the UK.

Pharmacology

Methaqualone is a quinazolinone, chemically distinct from both barbiturates and benzodiazepines, but it acts on the same broad system: it's a positive allosteric modulator at certain GABA-A receptors, enhancing the effect of the brain's main inhibitory neurotransmitter and producing dose-dependent sedation. It is also a negative allosteric modulator (excitatory) at certain others, unlike benzodiazepines. Recent structural biology work has found it binds at a transmembrane site between the receptor and subunits, the same site used by general anaesthetics propofol and etomidate which helps explain why it behaves more like a barbiturate/general anesthetic than a benzodiazepine in terms of overdose risk and safety margin. It's highly protein-bound in blood (roughly 70–80%) and has a notably long, biphasic elimination profile with an initial phase of around 10–40 hours followed by a slower terminal phase of around 20–60 hours meaning effects and residual impairment can last, and drug can accumulate in the body, well beyond a single dose's "high." Historically, oral onset was around 30 minutes with a main effect duration of roughly 5–8 hours, though this varied with dose and tolerance. We have very little data for designer analogues like Methoxyqualone which are increasingly being sold as quaaludes.

Harm Reduction

• Assume it isn't methaqualone unless proven otherwise. As above, this is the single most important harm-reduction point for anyone encountering "quaaludes" today outside South Africa's illicit Mandrax supply. You likely don't know what you actually have. Drug-checking services (e.g. WEDINOS: https://www.wedinos.wales) can identify what's actually in a sample.
• Avoid combining with any other CNS depressant (alcohol, benzodiazepines, opioids, GHB/GBL, other sedatives). This combination was the leading cause of methaqualone-related deaths historically the sedative and respiratory-depressant effects stack, and awareness of "how much you've taken" degrades well before consciousness does.
• Don't use alone. Given the risk of profound sedation and loss of consciousness, having someone sober present matters.
• Be aware of the long half-life. Because methaqualone (if genuine) clears slowly and can accumulate, redosing to "boost" a flagging effect carries real overdose risk. What feels like a fading high may not reflect how much is still in the body.
• If someone becomes unresponsive: put them in the recovery position, monitor breathing, and call emergency services immediately. Consider Naloxone use as it is possible opioids could be sold as methaqualone. Overdose presentation can look different to typical sedative overdoses and can resemble barbiturate toxicity with less cardiac/respiratory depression and more motor disturbance including hypertonia and hyperreflexia. Severe overdose can present as agitation and seizures rather than a classic “floppy, unresponsive” picture.
• Don't stop heavy, regular use abruptly. If someone has been using heavily and regularly enough to be dependent, sudden cessation can trigger a dangerous withdrawal (including seizures). This needs medical supervision, ideally through a drug service, rather than being managed alone.
• Route-specific note (South Africa/"white pipe"): Smoking methaqualone with cannabis is reported to produce a faster, more intense effect, which correspondingly narrows the margin for judging dose and increases overdose/accident risk compared with oral use.

History

Methaqualone was synthesised in India in the 50’s by researchers screening compounds for antimalarial activity, and its sedative properties were identified soon after. UK pharmaceutical companies began marketing it from the mid-1960s (as Malsed, Malsedin, Renoval, and, combined with an antihistamine, Mandrax), and it reached the US market in 1965, becoming known by the brand name Quaalude from 1972. Recreational and non-medical use grew rapidly through the 1970s in both countries, closely tied to club and disco culture in the US and increasingly linked to overdose, dependence, and diversion from legitimate prescriptions via so-called "stress clinics." The US moved methaqualone to Schedule II in 1973 and then to Schedule I in 1984, ending legal manufacture; the UK similarly tightened control, and it is currently listed as Class B under the Misuse of Drugs Act.

Methaqualone's trajectory in South Africa was different and its legacy there continues today. Introduced under the Mandrax brand and made illegal in 1971, methaqualone (mixed with cannabis and smoked as "white pipe") became and remains one of the most widely used illicit drugs in South Africa, consistently ranking among the top drugs of concern in national treatment-admission data. Because domestic manufacture is relatively straightforward and demand has remained high, South Africa continues to see large-scale trafficking and seizures of methaqualone and its precursor chemicals (notably anthranilic acid); as recently as May 2026, South African authorities intercepted what was reported as the country's largest-ever single drug seizure, a shipment of methaqualone precursor material valued at close to R1 billion, alongside other major seizures of finished Mandrax product and clandestine lab busts in preceding years.

Law

• Class B

Possible offences

• Possession
  • Maximum sentence – 5 years/fine/both
• Possession With Intent To Supply
  • Maximum sentence – 14 years / fine / both
• Supply (including being concerned in supply, conspiracy to supply, aggravated supply and offer to supply)
  • Maximum sentence – 14 years / fine / both
• Production
  • Maximum sentence – 14 years / fine / both

In practice maximum sentences are rarely used, for more detailed and accurate information go to our sentencing page.